Skip to main content
For Healthcare Professionals
Banner-Background

OVERALL POPULATION

JASCAYD® 18 mg improved survival as shown by a nominally significant reduction in risk of death vs placebo at the end of trial analysis1

The key secondary endpoint (time to first acute ILD exacerbation, first hospitalization for respiratory cause, or death over duration of trial) was not met. The analyses of the secondary and further endpoints of time to death and time to progression were not part of confirmatory testing and are explorative in nature.2

secondary-endpoint-ppf-with-actute-ild-new-death
secondary-endpoint-ppf-with-actute-ild-new-death

ILD, interstitial lung disease.

JASCAYD® improved survival as demonstrated by an early and sustained reduction in risk of death vs placebo at the end of trial analysis1

Quicklinks
PPF-Line-graph-July-CCDS
PPF-Line-graph-July-CCDS

WITHOUT NINTEDANIB

JASCAYD® 18 mg without nintedanib improved survival shown by a nominally significant reduction in risk of death at the end of trial analysis1

Secondary-endpoint-PPF-NO-ninte-Mortality
Secondary-endpoint-PPF-NO-ninte-Mortality

WITH NINTEDANIB

JASCAYD® 18 mg with nintedanib improved survival shown by a numerical reduction in risk of death at the end of trial analysis1

Secondary-endpoint-PPF-WITH-ninte-Mortality
Secondary-endpoint-PPF-WITH-ninte-Mortality
Quicklinks
References

  1. Wijsenbeek MS, Assassi S, Azuma A, et al. Effect of nerandomilast on clinical outcomes in patients with progressive pulmonary fibrosis (PPF): results from the final database lock of the FIBRONEER-ILD trial. 2025. Presented at: European Respiratory Society (ERS) International Congress; September 2025; Vienna, Austria. Poster available from: https://www.globalmedcomms.com/respiratory/ERS2025/Wijsenbeek1.

  2. Maher TM, Assassi S, Azuma A, et al. FIBRONEER-ILD Trial Investigators. Nerandomilast in patients with progressive pulmonary fibrosis. N Engl J Med. 2025;392(22):2203-2214.

  3. Wijsenbeek MS, Assassi S, Azuma A, et al. Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trial. Eur Respir J. Published online March 26, 2026.

MLR ID: PC-AE-102895
Expiry Date: 10/05/2028